Motor toxicities of chemotherapy-induced peripheral neuropathy (CIPN) are likely to lead to falls, deficits in physical performance (PP), and functional losses, according to a substudy of a phase 3 clinical trial in patients with CIPN reported at the 2012 Annual Meeting of the American Society of Clinical Oncology.1
Idiopathic thrombocytopenic purpura (ITP), now more commonly referred to as immune thrombocytopenia, is defined as a hemorrhagic disorder in which there is a pronounced reduction in circulating blood platelets due to the presence in blood plasma of a substance that agglutinates platelets.1 Despite this definition, the risk of bleeding in patients with ITP seems dis proportionately low, compared with the circulating platelet counts.
To sign up for our newsletter or print publications, please enter your contact information below.